Factor VIIIMaleThe Haemophilia Centre of Western Denmark is currently concerned with the diagnosis, treatment and social problems of 133 patients with haemophilia A. Of these patients 9.8% presented with an inhibiting antibody towards the factor VIII coagulant antigen. They thus all belong to the ...
PATIENTS with factor VIII deficiency and prolonged skin bleeding time (von Willebrand's syndrome) who receive fresh blood or plasma from normal donors or from patients with hæmophilia A with very low factor VIII activity show a much higher factor VIII activity in their plasma than could possi...
not affect secretion, although the specific activity of factor VIII was slightly increased[45], Thus, the presence of complex oligosaccharide was not required for secretion or functional activity of factor VIII.A23187treatment inhibited addition of serine/threonine (O)-linked glycans to factor VIII....
The Coatest SP4 Factor VIII kit (Chromogenix, Bedford, MA) was used to measure FVIII activity in conditioned media. WT mouse plasma was used as standards for activity assays. The VisuLize FVIII antigen kit (Affinity Biologicals, Ancaster, Canada) was used to analyze the antigen levels of ...
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to... SC Gouw,HMVD Berg,...
Von Willebrand factor (vWF) concentrates (I) containing Factor VIII:C (FVIII:C) are obtained by fractional precipitation from a liquid containing FVIII:C and vWF; and have an elevated content of high molecular multimers of vWF and a ratio of vWF:RCoF (ristocetin cofactor) activity to vWF:Ag...
of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. ...
Hilgartner, M., Knatterud, G. L. and the FEIBA Study Group. 1983. The use of factor VIII by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitor. Blood 61:36–40. PubMedCASGoogle Scholar ...
4359463Stabilization of Factor VIII activity in whole blood or blood plasma1982-11-16Rock424/529 4348384Pharmaceutical composition for oral administration containing coagulation factor VIII or IX1982-09-07Horikoshi et al.530/383 4305871Method of selectively increasing yield and purity of certain cryopreci...
GEL FILTRATION OF HEAT-TREATED FACTOR VIII PURPOSE: To obtain with high yield the title factor contg. no infectious action substance and being highly purified without damaging the activity by applying a mild treatment in which heat treatment for viral inactivation and gel filtrat... K Gerukaa,B...